



Penn Medicine

Perelman School of Medicine
University of Pennsylvania Health System

Edward A. Stadtmauer, MD
*Professor of Medicine
Chief, Hematologic Malignancies Section
Hematology-Oncology Division
Co-Leader, Hematologic Malignancies Program
and Translational Center of Excellence
Abramson Cancer Center*

June 11, 2020

I am writing to invite you to take part in the pilot group for a research study we are conducting at the University of Pennsylvania Abramson Cancer Center for patients with multiple myeloma. We are conducting this study to understand the financial problems faced by multiple myeloma patients who are receiving treatment for their myeloma.

We are looking for multiple myeloma patients over the age of 18 who have received treatment for myeloma for at least the past 90 days and who are receiving at least some of their multiple myeloma care at the University of Pennsylvania's Abramson Cancer Center. Participation includes completing a questionnaire about the cost of receiving multiple myeloma care, insurance coverage and benefits, and how multiple myeloma affects your quality of life. Additionally, we understand that the evolving COVID-19 pandemic significantly impacts the lives of many patients and the survey contains a few questions about how the COVID-19 pandemic has impacted you.

To participate, please go to: <https://redcap.med.upenn.edu/surveys/?s=ARARF49JXJ>. We ask that you complete the survey in the next 3 weeks, by July 3, 2020.

You will not receive any personal health benefits and there are no medications involved in this study. Whether you participate or not will have no effect on the medical care you receive at the center where you receive your care. Your responses will be used to help guide further refinement of the study and **may be** included in the final study analysis. If have any questions please contact our office at Myeloma.Cost.Study@penmedicine.upenn.edu or phone (215) 349-8334.

We hope that the results will help us understand multiple myeloma better, and benefit patients with multiple myeloma in the future.

Sincerely,

Edward Stadtmauer, MD and the Multiple Myeloma Financial Toxicity Study Team